TW202246332A - 抗trpv6單株抗體及其應用 - Google Patents

抗trpv6單株抗體及其應用 Download PDF

Info

Publication number
TW202246332A
TW202246332A TW111101701A TW111101701A TW202246332A TW 202246332 A TW202246332 A TW 202246332A TW 111101701 A TW111101701 A TW 111101701A TW 111101701 A TW111101701 A TW 111101701A TW 202246332 A TW202246332 A TW 202246332A
Authority
TW
Taiwan
Prior art keywords
antibody
seq
antigen
binding fragment
trpv6
Prior art date
Application number
TW111101701A
Other languages
English (en)
Chinese (zh)
Inventor
黃保華
譚巍
王中波
王偉
Original Assignee
大陸商同宜醫藥（蘇州）有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 大陸商同宜醫藥（蘇州）有限公司 filed Critical 大陸商同宜醫藥（蘇州）有限公司
Publication of TW202246332A publication Critical patent/TW202246332A/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW111101701A 2021-01-15 2022-01-14 抗trpv6單株抗體及其應用 TW202246332A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN2021072249 2021-01-15
WOPCT/CN2021/072249 2021-01-15
CN202210029357.7 2022-01-11
CN202210029357 2022-01-11

Publications (1)

Publication Number Publication Date
TW202246332A true TW202246332A (zh) 2022-12-01

Family

ID=82447968

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111101701A TW202246332A (zh) 2021-01-15 2022-01-14 抗trpv6單株抗體及其應用

Country Status (8)

Country Link
US (1) US20260116965A1 (https=)
EP (1) EP4293044A4 (https=)
JP (1) JP2024505430A (https=)
KR (1) KR20230132450A (https=)
CN (1) CN116802277A (https=)
CA (1) CA3206472A1 (https=)
TW (1) TW202246332A (https=)
WO (1) WO2022152236A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022365387A1 (en) * 2021-10-14 2024-05-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies against extracellular epitopes of human trpv6 channel and their diagnostic and therapeutic uses

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1229386C (zh) * 2002-09-16 2005-11-30 上海新世界基因技术开发有限公司 具有抑癌功能的新的人蛋白及其编码序列
EP2445932B1 (en) * 2009-06-26 2018-02-28 Soricimed Biopharma Inc. Soricidin derived peptides and methods for the detection of trpv-6 cancers and drug delivery
CN105399798B (zh) * 2015-11-24 2019-11-08 广东药科大学 Trpc3抗原多肽和抗trpc3的单克隆抗体
AU2022365387A1 (en) * 2021-10-14 2024-05-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies against extracellular epitopes of human trpv6 channel and their diagnostic and therapeutic uses

Also Published As

Publication number Publication date
JP2024505430A (ja) 2024-02-06
CN116802277A (zh) 2023-09-22
CA3206472A1 (en) 2022-07-21
EP4293044A4 (en) 2025-05-28
US20260116965A1 (en) 2026-04-30
KR20230132450A (ko) 2023-09-15
EP4293044A1 (en) 2023-12-20
WO2022152236A1 (zh) 2022-07-21

Similar Documents

Publication Publication Date Title
CA2855699C (en) Anti-human trop-2 antibody having an antitumor activity in vivo
EP2868667B1 (en) Therapeutic agent for anemia including renal anemia and cancer-induced anemia which contains anti-bmp9 antibody as active ingredient
JP4620591B2 (ja) ヒトインスリン様成長因子に対する遺伝子組換え抗体
JP4335130B2 (ja) ヒトインスリン様成長因子に対する抗体
JPWO2008114733A1 (ja) 抗Ｃｌａｕｄｉｎ−４抗体
CA2798778A1 (en) Anti-human trop-2 antibody having anti-tumor activity in vivo
TW201127402A (en) Anti-CD27 humanized monoclonal antibody
JP2010523096A (ja) 抗ＥｐＣＡＭ抗体およびその使用
CN113735971A (zh) 抗ck18蛋白单克隆抗体及其细胞株、制备方法和应用
KR102486507B1 (ko) 플렉틴-1 결합 항체 및 그의 용도
WO2014169494A1 (zh) 特异性识别egfr突变蛋白的单克隆抗体、制备方法及其应用
CN112940125B (zh) 抗vista蛋白的单克隆抗体及其细胞株、制备方法和应用
TW202246332A (zh) 抗trpv6單株抗體及其應用
KR102254905B1 (ko) Smo 단백질의 특이적 에피토프, 이를 인지하는 항체 및 이를 포함하는 조성물
WO2014047973A1 (zh) 特异性识别B-Raf突变蛋白的单克隆抗体、制备方法及其应用
KR20130135869A (ko) 항 단쇄 제4형 콜라겐 폴리펩타이드 항체 및 이를 포함하는 종양의 진단, 예방 또는 치료용 약제
WO2014146487A1 (zh) 抗细胞表面异位表达的单克隆抗体及其制备方法和用途
CN119604529A (zh) 抗体、其抗原结合片段及其药物用途
US8093361B2 (en) Anti-perp antibody
HK40105295A (en) Anti-trpv6 monoclonal antibody and application thereof
US20250092124A1 (en) Antibody molecule against growth and differentiation factor 15 and use thereof
US8093362B2 (en) Anti-PERP recombinant antibody
RU2790326C2 (ru) Анти-сd3-антитело и молекула, содержащая это антитело
JP2007320850A (ja) 抗エフリンｂ２抗体
EP1160572A1 (en) Diagnostics and remedies for leukemia